SANTA CLARA, Calif. - Agilent Technologies Inc. (NYSE: NYSE:A), a provider of analytical and clinical laboratory technologies, announced the appointment of Simon May as president of its Diagnostics and Genomics Group (DGG). May will officially join the company on Monday, following his previous role at Bio-Rad Laboratories (NYSE:BIO).
Simon May brings extensive experience from his tenure at Bio-Rad Laboratories, where he served as executive vice president and president of the Life Science Group. His previous positions at Bio-Rad included senior vice president and general manager of the Digital Biology Group, as well as senior vice president of Global Commercial Operations.
May's career in the industry spans over a decade at Thermo Fisher Scientific (NYSE:TMO) and time at MWG Biotech, beginning in laboratory roles and progressing through sales, product management, and business leadership.
Agilent's COO and CEO-elect, Padraig McDonnell, expressed confidence in May's qualifications for the role, highlighting his "deep technical knowledge" and his emphasis on strategy and operational excellence. McDonnell anticipates that May's expertise will be advantageous to Agilent as the company seeks to expand its reach and impact in the life sciences sector.
May's academic background includes a bachelor's degree and a doctorate in genetics/molecular biology from the University of Liverpool, England. He also completed a postdoctoral research fellowship at the same institution.
Agilent Technologies, which reported revenues of $6.83 billion in fiscal 2023 and employs around 18,000 people globally, is known for its contributions to the life sciences through its instruments, software, services, and expertise. The company aims to provide answers to complex questions in the field of science.
This announcement is based on a press release statement.
InvestingPro Insights
As Agilent Technologies Inc. (NYSE: A) welcomes Simon May to lead its Diagnostics and Genomics Group, the company's financial health and market performance provide a backdrop to the strategic appointment. With a market cap of $40.37 billion, Agilent stands as a significant player in the analytical and clinical laboratory technology space.
InvestingPro data shows that Agilent has a price-to-earnings (P/E) ratio of 32.82, reflecting a high earnings multiple that suggests investors have high expectations of the company's future earnings growth. This is further supported by the adjusted P/E ratio for the last twelve months as of Q1 2024, which is slightly lower at 30.93. The company's commitment to returning value to shareholders is evident through its dividend yield of 0.69%, with a recent dividend growth of 4.89%, maintaining dividend payments for 13 consecutive years—an InvestingPro Tip worth noting.
Another InvestingPro Tip highlights that the company's stock generally trades with low price volatility, which could be appealing to investors looking for stable investment options in the current market.
For those interested in deeper analysis and additional InvestingPro Tips, Agilent's profile on Investing.com offers further insights. There are 14 additional tips available, which can provide investors with a more comprehensive understanding of the company's financials and market performance. Users can access these insights and benefit from an additional 10% off a yearly or biyearly Pro and Pro+ subscription by using the coupon code PRONEWS24.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.